Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to Assess of Long-term impact post COVID for patients and health care professionals.The patients and medical staff will be followed for 2 years in order to provide clinical and paraclinical data not yet published in the literature.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Symptomatic COVID-19 infection confirmed or probable | Patients and medical staff having symptomatic COVID-19 infection confirmed (by RT-PCR or ELISA serology) or probable (CT criteria) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Diagnostic Test: serology test for COVID-19 | Diagnostic Test | a serology test will be performed at M3 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of post-traumatic stress symptoms (Post traumatic Stress Disorder (PTSD) scale) at M3 for patients and caregivers | measure used to assess symptoms of post-traumatic stress disorder. Individuals should rate their experience with each of the 17 symptoms of PTSD on a scale of 1 to 5 (1 = not at all, 2 = a little, 3 = moderately, 4 = a little, and 5 = extremely) versus to a specific traumatic event | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of post-traumatic stress symptoms (PTSD scale) at M12 and M24 for patients and caregivers | 12 and 24 months | |
| Change from M3 in the score of the mental (MCS), physical (PCS) components and the scores of the individual domains of the questionnaire SF36 to M12 and M24 for the entire study population |
| Measure | Description | Time Frame |
|---|---|---|
| Change from M3 score measuring anxiety (HAD-A) and depression score (HAD-D) to M12 and M24 for patients and caregivers. | HAD-A score measuring anxiety (example "I feel tense or nervous") and HAD-D score for depression (example "I have the impression of operating in slow motion").
| 12 and 24 months |
Inclusion Criteria:
Exclusion Criteria:
-Subject to a measure for the protection of justice
Not provided
Not provided
Not provided
Patient and medical staff with confirmed or probable COVID-19 infection
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Hervé PEGLIASCO | Hôpital Europeen Marseille | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| BENNANI | Marseille | 13003 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| 12 and 24 months |
| % of patients presenting a positive result by ELISA serology (= without distinction of IgG, IgM and IgA) | 3 months |
| Comparison of M0 chest CT results at each follow-up for the entire study population | 24 months |
| Change from M3 in the B-IPQ score at M12 and M24 for patients and caregivers. | The Brief Illness Perception Questionnaire (B-IPQ) includes 9 items that assess different components of "perception of the disease"( score 0 to 10 for each items) | 12 and 24 months |
| Evaluation of the microbiotic signature according to the severity of the disease at M3, M6 and M12 | 6 and 12 months |
| Evaluation of the fatigue EVA score and quality of life (SF36) at M6 and M12 | score from 0 to 10 (0 not tired, 10 max tired) | 6 and 12 months |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |